卡培他滨节拍化疗联合奥沙利铂传统化疗在晚期结肠癌中的研究

Research on capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy in patients with advanced colon cancer

目的探讨卡培他滨节拍化疗联合奥沙利铂传统化疗在晚期结肠癌中的研究。方法选取2014年8月_2016年8月在我院诊治的晚期结肠癌患者60例，采用随机数字法分为研究组（30例）和对照组（30例），研究组患者给予卡培他滨节拍化疗联合奥沙利铂进行化疗，对照组患者给予卡培他滨传统剂量联合奥沙利铂进行化疗，比较2组患者的总有效率（RR）、疾病控制率（DCR）、KPS评分、无进展生存期（PFS）及化疗期间出现的不良反应。结果研究组的RR为40％，对照组为16．67％，差异有统计学意义（P〈0．05）；研究组的DCR为53．33％，对照组为26．67％，差异具有统计学意义（P〈0．05）；2组患者在治疗前KPS评分相比，差异无统计学意义（P〉0．05），治疗后，研究组患者的KPS评分显著高于对照组（P〈0．05）；研究组患者的PFS为（10．8±3．4）月，对照组为（8．3±2．5）月，差异有统计学意义（P〈0．05）；与对照组相比，研究组患者在胃肠道反应、白细胞降低、手足综合征、免疫力下降及神经毒性等不良反应方面差异有统计学意义（P〈0．05）。结论卡培他滨节拍化疗联合奥沙利铂传统化疗对晚期结肠癌的临床疗效较好且安全性相对较高。

Objective To investigate the effects of capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy on patients with advanced colon cancer. Methods A total of 60 advanced colon cancer patients who were admitted in our hospital from August 2014 to August 2016 were collected and randomly divided into a research group and a control group （ n = 30）. The research group was given eapecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy, while the control group was provided with traditional doses of capecitabine combined with oxaliplatin traditional chemotherapy. Then, both groups were compared for the response rate （RR） , disease control rate （ DCR）, KPS score, progression free survival （PFS） and adverse reactions during treatment. Results The RR was 40% for the research group which was significantly different from 16.67% for the control （ P 〈 0.05 ）. The DCR was 53.33% for the research group which was significantly different from 26.67% for the control （P 〈 0.05 ）. Before treat- ment, no statistical difference was found as to KPS between the two groups （ P 〉 0. 05 ）. However, after treatment, the research group was remarkable higher KPS scores than the control group （ P 〈 0.05 ）. The PFS was （ 10.8 ± 3.4 ） months for the research group which was significantly different from （ 8.3 ± 2.5 ） months for the control （ P 〈 0.05 ）. Compared with the control group, statistical differences were found as to gastrointestinal reaction, leukocyte count reduction, hand - foot syndrome, weakened immunity, neurotoxicity and other adverse reactions （ P 〈0. 05 ）. Conclusions Capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy is effective and safe to treat advanced colon cancer,